The American Academy of Pediatrics believes the time has come for the federal government to reclassify marijuana in order to facilitate research. In a recent policy statement, the national committee on substance abuse said that while they do not support medical marijuana outside the regulatory confines of the United States Food and Drug Administration, they do recommend the government downgrade the Schedule I classification of the herb, so that science can begin to properly explore its health potential.
Although the health society is adamant that it does not support the concept of medical marijuana as 23 states and the District of Columbia have come to understand it, they are recommending the Drug Enforcement Administration downgrade the classification of cannabis to a Schedule II controlled substance because they realize “cannabinoid administration” may be the only effective recourse for children suffering from debilitating or life-threatening conditions.
“A Schedule 1 listing means there’s no medical use or helpful indications, but we know that’s not true because there has been limited evidence showing [marijuana] may be helpful for certain conditions in adults,” Dr. Seth Ammerman, a co-author of the study, told The Wall Street Journal.
“By placing this on Schedule 2, it would allow the FDA to be involved [in pediatric research] as the agency is in any study,” he continued. “Unless scheduling changes, this won’t happen. And there could be therapeutic benefits. The AAP is not opposed to medical marijuana, per se, but we feel it’s important that this be explored within the [framework of the] FDA process, where you have standardization.”
Perhaps the most common disease discussed in relation to children and marijuana is Epilepsy. In early 2014, the Epilepsy Foundation released a similar statement calling for the DEA to reconsider the Schedule I classification of marijuana in order to promote research. Yet, even though more states have legalized the herb for the sole purpose of treating epileptic children, the Obama Administration has done nothing to initiate any level of reform to the Controlled Substances Act.
In the meantime, the federal government has allowed GW Pharmaceuticals to conduct clinical trials in the United States with their cannabis-based epilepsy drug Epidiolex, bringing attention to corporate corruption that stands in the way of a nationwide medical marijuana program. Once the FDA puts its final stamp of approval on this medicine, which is expected, the DEA will simply classify it a Schedule II or III substance in order to bring it to market.
The AAP statement also recommends that marijuana be decriminalized across the nation, and “encourages pediatricians to advocate for laws that prevent harsh criminal penalties for possession or use of marijuana.”
Thai Police Give Researchers 220 Pounds Of Seized Marijuana
Police in Massachusetts Make Super Troopers Reference After Recovering Two Pounds of Weed
Tilray Stock Jumps After News of Exporting CBD to Australia for Epileptic Children
How Many States Allow Medical Marijuana?
Malaysian Court Sentences Man to Death for Distributing Free Cannabis Oil
Canadian Dispensary Clerk Fights off Three Burglars With a Giant Bong
Hot Pot Products: 4 Must-Haves for Cannabis Cultivators
Study Suggests CBD May Have Antipsychotic Effect in High-Risk Individuals
Guides6 days ago
What Do The Colors of Marijuana Mean?
Celebrities6 days ago
Kristen Bell Opens Up About Weekly Cannabis Use and Exploring Other Drugs
Strains5 days ago
9 Colorful Weed Strains To Brighten Your Day
News5 days ago
First Clinical Trial of MDMA Treatment for Autistic Adults Sees Success
News6 days ago
New Report Says Concentrates are the Fast Growing Favorite Among Consumers
News5 days ago
Study Finds Magic Mushrooms Could Aid in Smoking Cessation
Dispensaries5 days ago
First Medical Cannabis Dispensary Set to Open in Brooklyn By End of Year
Legalization7 days ago
New Jersey Lawmakers Draft New and Improved Marijuana Legalization Bill